Laura E Armstrong1,2, Grace L Guo1,2,3. 1. Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey. 2. Environmental and Occupational Health Science Institute, Rutgers University, Piscataway, New Jersey. 3. Center for Lipid Research, School of Environmental and Biological Sciences, Rutgers University, New Brunswick, New Jersey.
Abstract
PURPOSE OF REVIEW: About 15-25% of patients with simple steatosis of non-alcoholic fatty liver disease progresses to non-alcoholic steatohepatitis (NASH), and the underlying mechanism for this progression has not been elucidated. NASH ultimately could progress to cirrhosis, an irreversible condition. RECENT FINDINGS: Farnesoid X receptor (FXR) has been studied for its role in modulating inflammation, and the expression of FXR is down-regulated during NASH development. FXR deficiency has shown to progress and exacerbate NASH development, and FXR activation has been protective against liver inflammation associated with NASH. The expression of factors in both the adaptive and innate immune response in the liver are regulated in a FXR-dependent and -independent manner. SUMMARY: Therefore, understanding key signaling pathways of liver inflammation in NASH is important to determine essential components that predispose, progress, or exacerbate NASH. FXR has been identified as a therapeutic target for NASH to prevent liver inflammation.
PURPOSE OF REVIEW: About 15-25% of patients with simple steatosis of non-alcoholic fatty liver disease progresses to non-alcoholic steatohepatitis (NASH), and the underlying mechanism for this progression has not been elucidated. NASH ultimately could progress to cirrhosis, an irreversible condition. RECENT FINDINGS:Farnesoid X receptor (FXR) has been studied for its role in modulating inflammation, and the expression of FXR is down-regulated during NASH development. FXR deficiency has shown to progress and exacerbate NASH development, and FXR activation has been protective against liver inflammation associated with NASH. The expression of factors in both the adaptive and innate immune response in the liver are regulated in a FXR-dependent and -independent manner. SUMMARY: Therefore, understanding key signaling pathways of liver inflammation in NASH is important to determine essential components that predispose, progress, or exacerbate NASH. FXR has been identified as a therapeutic target for NASH to prevent liver inflammation.
Authors: John Willy Haukeland; Jan Kristian Damås; Zbigniew Konopski; Else Marit Løberg; Terese Haaland; Ingeborg Goverud; Peter A Torjesen; Kåre Birkeland; Kristian Bjøro; Pål Aukrust Journal: J Hepatol Date: 2006-03-20 Impact factor: 25.083
Authors: Kirstine S Tølbøl; Birgit Stierstorfer; Jörg F Rippmann; Sanne S Veidal; Kristoffer T G Rigbolt; Tanja Schönberger; Matthew P Gillum; Henrik H Hansen; Niels Vrang; Jacob Jelsing; Michael Feigh; Andre Broermann Journal: Dig Dis Sci Date: 2018-12-03 Impact factor: 3.199
Authors: Glenn S Gerhard; Ivana Malenica; Lorida Llaci; Xin Chu; Anthony T Petrick; Christopher D Still; Johanna K DiStefano Journal: Clin Epigenetics Date: 2018-07-13 Impact factor: 6.551